Bipolar Affective Disorder

Overview & Definition

Bipolar affective disorder (BPAD), historically called manic-depressive illness (Kraepelin, 1899), is a chronic, relapsing, episodic mood disorder defined pathognomonically by the occurrence of at least one manic (Bipolar I) or hypomanic (Bipolar II) episode. The illness is "bipolar" because mood swings between two poles — the manic pole (elevation/expansion/irritability with increased energy) and the depressive pole (lowered mood, anhedonia, retardation). Crucially, it is the manic/hypomanic pole that defines the diagnosis: a patient with recurrent depression who has had even one hypomanic episode has Bipolar II, not unipolar depression — a distinction that changes treatment, because antidepressants given without mood-stabiliser cover can precipitate mania, mixed states and rapid cycling.^[1][2]

The clinical task has four parts: (1) recognise the elevated pole (mania/hypomania), which is frequently missed — patients seek help in depression and under-report past highs, so most bipolar patients are misdiagnosed with unipolar depression for 8 to 10 years on average; (2) exclude organic and substance-induced causes of elevation (thyrotoxicosis, corticosteroids, stimulants); (3) phase-specific treatment — acute mania, acute bipolar depression and maintenance are treated with different drug hierarchies; and (4) reduce suicide risk and long-term harm through mood-stabiliser prophylaxis, psychoeducation and circadian-rhythm protection. Bipolar disorder carries the highest suicide rate of any psychiatric disorder (around 0.4% per year), so risk assessment is central to every contact.^[1][6]

^[1]

Classification

Bipolar disorders are classified in DSM-5-TR and ICD-11 along a spectrum defined by the severity/polarity of the highs, the presence of full manic episodes, and the chronicity of mood instability. The two axes examiners test are: (a) does the patient ever reach a full manic episode? (separates Bipolar I from II) and (b) are full episode criteria met? (separates Bipolar I/II from cyclothymia).^[2][11]

DSM-5-TR diagnostic criteria — manic episode (reproduced)

• Criterion A — a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least 1 week (or any duration if hospitalisation is necessary), present most of the day, nearly every day.
• Criterion B — during the mood disturbance, 3 or more of the following (4 if mood is only irritable) are present to a significant degree: (1) inflated self-esteem or grandiosity; (2) decreased need for sleep (feels rested after only a few hours — one of the most characteristic signs); (3) more talkative than usual or pressure of speech; (4) flight of ideas or subjective experience that thoughts are racing; (5) distractibility; (6) increase in goal-directed activity or psychomotor agitation; (7) excessive involvement in activities with high potential for painful consequences (sexual indiscretions, gambling, reckless spending, foolish investments).
• Criterion C — the disturbance is sufficiently severe to cause marked impairment in social/occupational functioning, OR necessitates hospitalisation, OR is associated with psychotic features.
• Criterion D — not attributable to substance or another medical condition.
• Criterion E — criteria are not met for a major depressive episode (but full depressive symptoms concurrent with mania = a manic episode with mixed features).^[2]

DSM-5-TR diagnostic criteria — hypomanic episode (reproduced)

• Criterion A — same mood/activity change as mania, but lasting at least 4 consecutive days, present most of the day, nearly every day.
• Criterion B — same 3-of-7 symptom list as mania.
• Criterion C — an unequivocal change in functioning that is uncharacteristic of the person.
• Criterion D — the disturbance is observable by others.
• Criterion E — not severe enough to cause marked impairment or hospitalisation, and there are no psychotic features (if either is present, it is by definition a manic episode).
• Criterion F — not attributable to substance or medical cause (antidepressant treatment that triggers elevation counts if it persists beyond the physiological drug effect).^[2]

The single examinable distinction: marked functional impairment, hospitalisation, or psychosis converts hypomania into mania, and Bipolar II into Bipolar I. ^[1]

Epidemiology & Risk Factors

Bipolar I has a lifetime prevalence of about 1%; the broad bipolar spectrum (I, II, cyclothymia and subthreshold forms) reaches 2 to 4%. The sex ratio is equal overall (unlike unipolar depression, which is 2:1 female), although Bipolar II and rapid cycling are more common in women. Mean age of onset is 15 to 30 years (earlier than unipolar depression), and onset after age 50 should prompt an aggressive search for an organic cause. Bipolar disorder accounts for a large share of global psychiatric disability and is a leading cause of years lost to disability in the 15 to 44 age band.^[1]

Risk factors (high-yield): ^[1]

Pathophysiology

Bipolar disorder is a heterogeneous, multisystem illness involving genetic susceptibility, monoamine dysregulation, circadian-rhythm disruption, abnormalities of intracellular signalling, neuroprogression and inflammation. No single mechanism explains it, but several interlocking models are examinable.^[1][4]

Genetics — the strongest single contributor

Bipolar disorder is a highly heritable major psychiatric disorder — a population-based Swedish twin study estimated heritability at 60.4% (95% CI 50.3 to 70.5), with no sex-specific genetic effects.^[40] It is polygenic: genome-wide association studies have replicated risk variants in CACNA1C, ODZ4 and NCAN, with strong evidence for a polygenic contribution of many small-effect alleles and substantial overlap of susceptibility with schizophrenia for individual risk alleles and polygenic risk.^[4] The high heritability underpins the cardinal clinical question — always ask about a family history of mood disorder, suicide or psychiatric admission.^[4]

Monoamine dysregulation — the classical model

Historically, the catecholamine hypothesis linked mania to excess noradrenaline and dopamine and depression to their deficiency. The pharmacological evidence: amphetamine and cocaine (which release dopamine and noradrenaline) produce a mania-like state; L-dopa can trigger mania in predisposed people; reserpine (which depletes monoamines) precipitated depression; and all effective antimanic antipsychotics block D2 receptors, while lithium dampens overactive second-messenger signalling downstream. The modern view is of regional, phase-dependent monoamine dysregulation rather than a simple global excess or deficiency. ^[1]

Kindling and behavioural sensitisation (Post)

The kindling / sensitisation model proposes that, like epilepsy, repeated mood episodes lower the threshold for further episodes, so that episodes become more frequent, more severe and more spontaneous over time. Early episodes may be triggered by clear psychosocial stress, but later ones arise without obvious triggers. This is the biological justification for early, continuous mood-stabiliser prophylaxis even after a first episode, and it explains why untreated illness is associated with cognitive decline and treatment resistance (neuroprogression). ^[1]

Circadian-rhythm disruption — core to bipolar

Disrupted biological rhythms are central, not incidental, to bipolar disorder. Reduced need for sleep is one of the most specific manic symptoms, sleep deprivation reliably precipitates mania, and childbirth (with its acute sleep loss) is a potent postpartum trigger. Variants in clock genes (CLOCK, BMAL1, PER3) and the response of bipolar patients to sleep deprivation, light therapy and social-rhythm therapy all implicate circadian machinery. Interpersonal and social rhythm therapy (IPSRT) was designed specifically to stabilise these rhythms. ^[1]

Intracellular signalling — why lithium works (high-yield)

Lithium's therapeutic action arises not from a single receptor but from intracellular second-messenger and kinase pathways. Lithium (the Li+ ion, given as lithium carbonate) substitutes for magnesium and inhibits two key enzymes: ^[1]

• Glycogen synthase kinase-3 (GSK-3β) — lithium is a direct GSK-3 inhibitor. Inhibition of GSK-3 increases neurotrophic factors (BDNF), anti-apoptotic Bcl-2, neurogenesis and circadian-gene regulation, and is considered a major contributor to lithium's neuroprotective and antimanic/prophylactic effect.
• Inositol monophosphatase (IMPase) — lithium depletes intracellular myo-inositol, dampening the phosphatidylinositol (PIP2/IP3/DAG) second-messenger cascade that amplifies neurotransmitter signalling (the "inositol depletion hypothesis"). ^[1]

These converging molecular effects — reduced GSK-3 activity, inositol depletion, enhanced BDNF/Bcl-2, normalisation of circadian-gene expression — explain how a single ion can stabilise mood across both poles. This molecular mechanism is a favourite viva question.^[3]

Neuroendocrine, structural and inflammatory changes

• HPA-axis dysregulation (elevated cortisol, non-suppression on the dexamethasone-suppression test) is most marked during depressive episodes.
• Structural neuroimaging: mild ventricular enlargement, white-matter hyperintensities (especially subcortical), reduced prefrontal cortical and anterior cingulate volume, amygdala enlargement and reduced hippocampal volume — findings that accumulate with episode count (neuroprogression).
• Inflammation and oxidative stress (the Berk group): raised CRP, cytokines (IL-6, TNF-α), oxidative damage and mitochondrial dysfunction are described; N-acetylcysteine (NAC) targets glutathione and shows benefit as an adjunct in bipolar depression, exemplifying this model.^[1]

Clinical Presentation

Bipolar disorder is episodic. Patients present in one of three phases — mania/hypomania, major depression, or euthymia (with residual symptoms) — and the history (especially collateral history, because patients under-report past highs) determines the diagnosis. ^[1]

Manic episode — DIGFAST (the high-yield mnemonic)

Other classical manic features: elevated/expansive or irritable mood (irritability is common and easily misread as aggression or borderline personality), hyper-religiosity, hypersexuality, bright/expensive/clashing clothing, increased appetite and libido, overspending (multiple credit cards, extravagant gifts), alcohol and substance misuse, psychotic symptoms that are typically mood-congruent (grandiose/religious delusions of wealth, power, divine mission; persecutory delusions), and complete lack of insight. First-rank-symptom-type thought disorder and passivity can occur, mimicking schizophrenia, but the prominent mood syndrome and the episodic course with full or near-full inter-episode recovery point to bipolar.^[2]

Hypomania — "mania lite"

The same symptoms as mania but less severe: observable change in functioning, no marked impairment, no psychotic features, no hospitalisation needed. The patient typically feels well or "better than well", is productive and creative, and rarely presents voluntarily — the history is usually uncovered by collateral or during assessment of a depressive episode. Ask every depressed patient: "Have you ever had periods of needing very little sleep yet feeling full of energy, being unusually productive or making impulsive decisions?" ^[1]

Bipolar depression

A major depressive episode in a bipolar patient is clinically similar to unipolar depression but tends to show more atypical features: hypersomnia (rather than insomnia), hyperphagia and weight gain, leaden paralysis (heavy limbs), psychomotor retardation, psychotic features, and more frequent, shorter, treatment-resistant episodes. The crucial point — depressive episodes dominate the morbidity of Bipolar II and carry the suicide risk, and they are routinely misdiagnosed as unipolar depression, leading to treatment that can precipitate mania. ^[1]

Mixed features (DSM-5) — a high-risk state

A mixed episode (DSM-5 now "with mixed features") is a manic/hypomanic episode with at least 3 depressive symptoms (e.g. sadness, anergia, hopelessness, suicidal ideation) OR a major depressive episode with at least 3 manic/hypomanic symptoms (e.g. elevated mood, grandiosity, flight of ideas, reduced sleep need). Mixed states carry an exceptionally high risk of suicide, respond poorly to antidepressants, and should be managed as mania (antipsychotic/mood stabiliser; avoid antidepressants).^[2]

Atypical presentations

• Postpartum onset — childbirth is a potent trigger; postpartum psychosis is strongly associated with bipolar disorder (a personal or family history of bipolar raises postpartum-psychosis risk 100-fold). Onset within 2 weeks; elation, confusion, delusions about the baby — an obstetric and psychiatric emergency.
• Adolescents — mood lability, irritability, explosive anger and mixed states; diagnosis is harder and overlaps with ADHD; a strong family history and episodic, distinct-from-baseline elevation support bipolar.
• Elderly — first-onset mania after 50 is almost always organic (stroke, tumour, steroids, thyrotoxicosis, dementia); investigate aggressively. Cognitive impairment may be comorbid or lithium-related.
• Rapid cycling — at least 4 mood episodes in 12 months; more common in women, associated with hypothyroidism, antidepressant use and substance use; responds poorly to lithium (favour valproate); affects 10 to 20% of bipolar patients.
• Comorbidity — substance misuse (in over half), anxiety disorders, ADHD, borderline and other personality disorders, migraine, metabolic syndrome. These complicate diagnosis and worsen prognosis. ^[1]

Differential Diagnosis

The cardinal diagnostic rule is: always exclude an organic or substance-induced cause for any first manic episode, then decide whether the elevation is primary (bipolar), secondary to a medical cause, or part of another psychiatric disorder (schizoaffective, personality disorder).^[2]

Distinguishing features examiners reward: (a) the temporal relationship between psychosis and mood (psychosis only with mood = bipolar; psychosis without mood = schizoaffective/schizophrenia); (b) presence of a clear manic/hypomanic episode (bipolar vs unipolar); (c) evidence of a substance or medical cause; (d) episodic vs continuous course; (e) level of inter-episode function. ^[1]

Clinical & Bedside Assessment

Bipolar disorder is a clinical diagnosis made from a careful psychiatric history (including collateral), a full mental state examination, physical examination and screening investigations to exclude organic causes. Collateral history is essential — patients under-report past highs, especially hypomania, which they experienced as pleasant and productive.^[2]

History — what to elicit: ^[1]

• Presenting episode: polarity (manic, depressive, mixed), onset, duration, precipitants (stress, sleep loss, substance, steroid, postpartum, antidepressant initiation).
• Lifetime mood history — the diagnosis lives here: chart every prior manic/hypomanic, depressive and mixed episode, hospitalisations, suicide attempts and the inter-episode baseline. Ask directly: "Have you ever had days or weeks of feeling unusually high, not needing sleep, full of energy, making big plans, or spending lots of money?"
• Substance and medication history — alcohol, cannabis, cocaine, amphetamines, anabolic steroids; current/recent antidepressants, stimulants, corticosteroids.
• Medical history — thyroid disease, neurological disease, head injury, autoimmune disease.
• Family history — bipolar disorder, depression, suicide, psychiatric admission (the strongest single risk factor).
• Psychosocial — relationships, employment, finances, debts incurred during mania, forensic history (during mania).
• Risk assessment (mandatory) — suicide (bipolar carries the highest rate), self-harm, neglect, risk to others (during mania), vulnerability (sexual/financial exploitation). ^[1]

Mental state examination in mania: ^[1]

• Appearance/behaviour — bright/clashing/expensive clothing, make-up, jewellery, psychomotor agitation, intrusiveness, overfamiliarity, disinhibition, singing, may be dishevelled if severe.
• Speech — pressured, loud, rapid, difficult to interrupt; flight of ideas; clang associations.
• Mood — euphoric, expansive, irritable (lability between them); subjective rating "10 out of 10".
• Thought — grandiose (special powers, wealth, divine mission), sometimes persecutory; flight of ideas, racing thoughts; usually no formal thought disorder, but can mimic schizophrenia if severe.
• Perception — mood-congruent delusions (grandiose, religious, persecutory); hallucinations possible; no clouding of consciousness (if clouded, think delirium/organic).
• Cognition — usually intact (impaired attention from distractibility); clouding or disorientation suggests organic.
• Insight — typically absent; poor adherence risk. ^[1]

Screening instruments: ^[1]

• Mood Disorder Questionnaire (MDQ) — a screening tool for bipolar spectrum in adults: 13 yes/no items covering manic/hypomanic symptoms, a question on whether symptoms co-occurred ("have several of these ever happened during the same period of time"), and a question on the resulting problem severity. A positive screen (yes to several items, co-occurrence, and moderate-or-severe resulting problem) warrants a structured diagnostic interview.
• Hypomania Checklist-32 (HCL-32) — 32-item checklist detecting past hypomanic episodes, helping separate Bipolar II from unipolar depression.
• Young Mania Rating Scale (YMRS) — the standard severity scale for mania (see Investigations). ^[1]

Investigations

There is no laboratory test for bipolar disorder — it is a clinical diagnosis. Investigations serve three purposes: (1) exclude organic causes of elevation/depression, (2) establish a safe baseline before mood-stabiliser treatment, and (3) monitor treatment toxicity.^[3]

Baseline (every patient, before mood stabilisers): ^[1]

• U&E, eGFR, creatinine — lithium is renally excreted; valproate and carbamazepine can affect the kidney/liver.
• LFTs — valproate (hepatotoxicity), carbamazepine.
• FBC — carbamazepine (leukopenia, aplastic anaemia), valproate (thrombocytopenia); lithium causes benign leukocytosis.
• TFTs (TSH, free T4) — exclude thyrotoxicosis as a cause of mania; lithium causes hypothyroidism.
• Calcium / PTH — lithium causes hyperparathyroidism.
• Glucose / HbA1c, fasting lipids, weight/BMI, waist circumference — antipsychotics cause metabolic syndrome.
• Pregnancy test (beta-hCG) in all women of childbearing potential — before lithium or valproate (both teratogenic).
• ECG — if cardiac disease, before QT-prolonging antipsychotics or lithium.
• Urinary drug screen — exclude stimulant-induced mania (cocaine, amphetamines).
• MRI brain — if first mania, atypical features, age over 50, focal neurology, or clouding of consciousness (exclude tumour, stroke, demyelination).
• Infection screen, autoimmune (ANA), syphilis serology, HIV — as guided by history. ^[1]

Drug levels (therapeutic drug monitoring): ^[1]

Young Mania Rating Scale (YMRS) — reproduced

The YMRS (Young, Biggs, Ziegler, Meyer, 1978) is the standard clinician-rated severity scale for mania.^[8] It has 11 items, scored on a 0 to 5 scale, but items 1 to 5 (and 6) are graded over a wider range in the original; in routine use the first 4 items are given double weight (scored 0, 2, 4, 6, 8) and items 5 to 11 are scored 0, 1, 2, 3, 4, giving a maximum total of 60:

1. Elevated mood (double-weighted)
2. Increased motor activity / energy (double-weighted)
3. Sexual interest (double-weighted)
4. Sleep (double-weighted)
5. Irritability
6. Speech (rate and amount)
7. Language–thought disorder
8. Content (of thought)
9. Disruptive–aggressive behaviour
10. Appearance
11. Insight ^[1]

Interpretation: a score below 12 generally indicates no or minimal mania; about 12 to 19 mild/moderate (hypomania range); about 20 to 25 moderate mania; and over 25 to 30 severe mania. The YMRS is used to diagnose severity and track response to antimanic treatment, not to make the categorical diagnosis. ^[1]

Depression scales used in bipolar depression: HAM-D (Hamilton Depression Rating Scale, 17-item), MADRS (Montgomery–Åsberg, less confounded by somatic side-effects), and the self-rated PHQ-9 — use with caution because somatic items (sleep, appetite, energy) overlap with mania. ^[1]

Management — Resuscitation

^{[14] [16] [30] [42]}

Acute mania is rarely a physiological emergency in the cardiovascular sense, but it is a behavioural and risk emergency — the priorities are safety, control of agitation/aggression, prevention of harm (suicide, recklessness, exploitation), exclusion of an organic cause, and rapid initiation of antimanic treatment.^[3][11]

Acute behavioural management (rapid tranquillisation) — stepwise: ^[15][16]

1. De-escalation first — non-pharmacological measures (calm, low-stimulus environment, verbal de-escalation by trained staff) should precede pharmacological intervention, and options range beyond the standard lorazepam–haloperidol–promethazine set to oral and inhaled/buccal alternatives.^[16]
2. Oral medication if accepted — an oral antipsychotic or benzodiazepine; the BAP/NAPICU consensus additionally lists oral-inhaled loxapine and buccal midazolam as options.^[16]
3. IM medication if oral refused / severe agitation — in the largest pragmatic trial, intramuscular lorazepam 4 mg was compared with intramuscular haloperidol 10 mg plus promethazine 25 to 50 mg: both left 96% tranquil or asleep at 4 hours, but the haloperidol–promethazine mix produced faster tranquillisation and more sleep (76% vs 45% asleep; RR 2.29).^[15] Intramuscular olanzapine 2.5 to 10 mg (up to 3 injections per 24 hours) calms agitation with less nonspecific sedation than lorazepam 2 mg; haloperidol 7.5 mg is the classic comparator.^[17]
4. Treat the underlying episode and monitor — every guideline stresses that rapid tranquillisation buys safety, not treatment: identify and start definitive antimanic therapy (below), and monitor vital signs and conscious level after parenteral sedation.^[16]

Safety and legal framework: ^[1]

• Admit under the Mental Health Act (UK Section 2 assessment, up to 28 days; Section 3 treatment, up to 6 months renewable; Section 5(2) inpatient holding power) when the patient lacks capacity, refuses admission, or there is risk to health, safety or others. Mania frequently impairs insight and capacity.
• Exclude organic causes — drug screen, glucose, U&E, calcium, TFTs, infection screen, MRI if atypical.
• Identify and treat the underlying episode (see Definitive Management).
• Reduce stimulation — single room, low lighting, remove valuables/credit cards, restrict phone access during acute mania to limit financial/sexual harm; constant observation if high suicide/self-harm risk. ^[1]

Management — Definitive & Stepwise

Bipolar disorder is managed phase-by-phase — acute mania, acute bipolar depression, and maintenance prophylaxis are treated with different drug hierarchies. A unifying principle: antidepressants must be used cautiously and always with mood-stabiliser cover, because they can precipitate mania, mixed states and rapid cycling.^[3][11]

Phase 1 — Acute mania (and mixed states)

Step 1 — STOP any antidepressant. Antidepressants are not recommended as monotherapy in bipolar disorder and can destabilise the mood; stop them (and review stimulants and corticosteroids) in an emerging manic episode.^[13][14]

Step 2 — Start an antipsychotic (the most effective drug class in acute mania). The Cipriani 2011 multiple-treatments meta-analysis (68 RCTs, 16,073 participants) found haloperidol (SMD −0.56), risperidone (−0.50), olanzapine (−0.43), lithium (−0.37), quetiapine (−0.37), aripiprazole (−0.37), carbamazepine (−0.36), asenapine (−0.30), valproate (−0.20) and ziprasidone (−0.20) all significantly more effective than placebo, whereas gabapentin, lamotrigine and topiramate were not. Haloperidol was the most effective and risperidone, olanzapine and haloperidol are among the best available options; olanzapine, risperidone and quetiapine caused fewer discontinuations than lithium or placebo. Antipsychotics were significantly more effective than mood stabilisers overall.^[5]

Step 3 — Add or start a mood stabiliser (onset over days to weeks; needed for ongoing control and prophylaxis). CANMAT/ISBD lists lithium, quetiapine and divalproex among first-line options for acute mania:^[14]

• Lithium — dose is individualised and guided by the standardised 12-hour serum concentration (fixed interval between last dose and blood sampling, sampled at the same hour).^[23] In the BALANCE maintenance trial the protocol lithium range was 0.4 to 1.0 mmol/L;^[7] a dose-response meta-analysis of six RCTs found recurrence risk of any mood episode falling from OR 0.50 at 0.60 mmol/L to OR 0.15 at 1.20 mmol/L.^[22]
• Valproate (semisodium) — oral loading with divalproex 20 mg/kg/day in divided doses reaches serum concentrations above 50 mg/L within 24 hours, with antimanic activity emerging within days; a randomised dose-finding study of bipolar mixed episodes titrated divalproex to 75 to 125 mcg/mL. Useful in rapid cycling (valproate is a standard option in lithium-resistant rapid cyclers); avoid in women of childbearing potential (teratogenic — see below).^[18][19][45]

Step 4 — Combination / refractory: in the BALANCE randomised trial, lithium plus valproate combination therapy and lithium monotherapy were both more likely to prevent relapse than valproate monotherapy (HR 0.59 combination vs valproate; HR 0.71 lithium vs valproate), while combination could neither reliably confirm nor refute a benefit over lithium alone (HR 0.82, p=0.27) — so combine, but lithium is the anchor.^[7] ECT is an evidence-based option for severe, refractory or life-threatening bipolar states, alongside newer brain-stimulation treatments.^[47]

Step 5 — Supportive: short-term adjunctive benzodiazepines (lorazepam 2 mg IM was the comparator arm of the olanzapine IM agitation trials; 4 mg IM in the rapid-tranquillisation trial) settle agitation and restore sleep while the antimanic agent takes effect.^[15][17]

Phase 2 — Acute bipolar depression

Bipolar depression is harder to treat than mania, carries most of the suicide risk, and antidepressants carry a switch risk.^[3]

First-line (CANMAT/ISBD 2018; network meta-analysis):^[14][30]

• Quetiapine — 300 or 600 mg/day both beat placebo in the BOLDER II trial of bipolar I/II depression; in the network meta-analysis quetiapine was also better than placebo at reducing treatment-emergent affective switch.^[30][33]
• Lurasidone — 20 to 60 mg/day or 80 to 120 mg/day both beat placebo on MADRS in bipolar I depression (low metabolic burden).^[30][31]
• Cariprazine — 1.5 or 3.0 mg/day beat placebo in a phase 3 trial of bipolar I depression (D3/D2 and 5-HT1A partial agonist).^[30][32]
• Olanzapine–fluoxetine combination — effective versus placebo for bipolar depression in the network meta-analysis.^[30]
• Lamotrigine and lithium — first-line options for bipolar I depression in CANMAT/ISBD 2018; note that in the bipolar-depression network meta-analysis lithium did not separate from placebo on response.^[14][30]
• Escitalopram, paroxetine, sertraline, aripiprazole, ziprasidone and gabapentin appear ineffective versus placebo in bipolar depression.^[30]

Antidepressants — not as monotherapy, and with caution: antidepressants are not recommended as monotherapy in bipolar disorder.^[13] In the STEP-BD randomised trial (Sachs 2007, NEJM), adding an antidepressant to a mood stabiliser gave durable recovery in 23.5% versus 27.3% with mood stabiliser plus placebo (P=0.40) — no added benefit — and rates of treatment-emergent affective switch were similar in the two groups.^[29] Stop any antidepressant if elevation emerges. In rapid cycling, antidepressant use is associated with onset or worsening of cycling — reduce or stop cycle-promoting agents.^[49]

Lamotrigine is valuable for bipolar depression and maintenance (prevents depressive relapse) but is not effective in acute mania;^[5] titrate slowly — rash is the key risk (below).^[43]

Phase 3 — Maintenance prophylaxis

After one definite manic episode, long-term prophylaxis is recommended (the kindling model justifies early, continuous treatment). Options:^[3][7]

• Lithium — the gold standard. It has the strongest evidence for long-term relapse prevention of any mood stabiliser.^[3] The BALANCE trial (Lancet 2010) found lithium monotherapy more likely to prevent relapse than valproate monotherapy (HR 0.71, p=0.0472; 59% vs 69% had an emergent mood episode) and combination therapy not clearly better than lithium alone (HR 0.82, p=0.27).^[7] Lithium also reduces suicide versus placebo (OR 0.13, 95% CI 0.03 to 0.66) and death from any cause (OR 0.38).^[6]
• Valproate — alternative or adjunct, especially for rapid cycling.^[45][49]
• Lamotrigine — first-line for maintenance in CANMAT/ISBD 2018, best for the depressive pole; titrate slowly and stop at the first sign of rash — benign rash occurs in about 8% versus 6% on placebo, and serious rash in up to 0.13% of bipolar trial patients.^[14][43][44]
• Antipsychotics — quetiapine, asenapine and aripiprazole are first-line maintenance options in CANMAT/ISBD 2018 (olanzapine and others also have maintenance data); a long-acting injectable addresses non-adherence, which affects over half of patients.^[13][14]
• Combination therapy (lithium plus valproate, or lithium plus an antipsychotic) for refractory or rapid-cycling illness — BALANCE supports lithium plus valproate over valproate alone.^[7][49]

Non-pharmacological maintenance: a strong evidence base exists for psychoeducation, cognitive-behavioural therapy, family-focused therapy, interpersonal and social rhythm therapy (IPSRT) and peer-support programmes.^[42]

• Psychoeducation — about the illness, early-warning signs, sleep hygiene, adherence, substance avoidance; reduces relapse and hospitalisation.^[42]
• Interpersonal and social rhythm therapy (IPSRT) — stabilises daily routines and the sleep–wake cycle; randomised in bipolar I disorder over 2 years.^[42]
• Cognitive behavioural therapy, family-focused therapy, peer support.^[42]
• Advance directives / crisis plans, relapse-prevention cards, regular mood monitoring.^[42]

Lithium — the drug to know cold

Specific Subtypes & Scenarios

• Bipolar I — at least one manic episode; treat the index manic episode (antipsychotic plus mood stabiliser), then lifelong maintenance (usually lithium). Antidepressants should generally be avoided without mood-stabiliser cover because of switch risk.
• Bipolar II — hypomania plus major depression; the depression dominates the morbidity and carries the suicide risk. Treat bipolar depression (quetiapine, lurasidine, lithium, lamotrigine) and give maintenance. Antidepressants are slightly less risky than in Bipolar I but still used cautiously.
• Cyclothymia — chronic subthreshold mood instability for over 2 years; psychoeducation, mood monitoring, and SSRI/lamotrigine or low-dose mood stabiliser for the depressive pole; watch for escalation to Bipolar I/II (15 to 50%).
• Rapid cycling (at least 4 episodes/year) — avoid antidepressants (they worsen it), check and treat hypothyroidism, favour valproate/lithium over antidepressants; combination therapy often needed.
• Mixed features — treat as mania (antipsychotic/mood stabiliser); antidepressants can worsen mixed states and increase suicide risk.
• Cyclothymia — chronic subthreshold mood instability (numerous hypomanic symptoms and numerous depressive symptoms) for at least 2 years without meeting full episode criteria; treat with psychoeducation and mood monitoring, watching for escalation to Bipolar I/II.^[12]
• Postpartum mania / psychosis — emergency: mother-and-baby admission, stop breastfeeding temporarily, antipsychotic plus mood stabiliser (avoid lithium/valproate in breastfeeding), ECT is highly effective and fast; risk of recurrence in future pregnancies is high (offer prophylaxis).
• Adolescent-onset bipolar — family history and clear episodic elevation support the diagnosis; mood stabilisers and atypical antipsychotics; avoid stimulants/antidepressants where possible; involve family. ^[1]

Complications & Pitfalls

Lithium toxicity (a narrow therapeutic index)

Lithium has a narrow therapeutic index (therapeutic serum range roughly 0.6 to 1.3 mmol/L). Poisoning typically arises from reduced renal elimination, prescribing error, drug-drug interactions or deliberate overdosage.^[21][50]

• Mild toxicity (about 1.5 to 2.5 mEq/L).
• Moderate toxicity (about 2.5 to 3.5 mEq/L).
• Severe intoxication (over 3.5 mEq/L) — renal replacement therapy should be considered in these specific poisoning conditions; neurologic injury from lithium poisoning can be permanent.^[21][50]

Management of lithium toxicity: lithium is fully filtered and partially reabsorbed by the kidney (handled like sodium), so intravenous fluids are the mainstay together with correcting precipitants.^[21] Extracorporeal treatment (haemodialysis is the preferred modality) is recommended in severe lithium poisoning, and specifically if kidney function is impaired and [Li] is over 4.0 mEq/L, or in the presence of decreased level of consciousness, seizures, or life-threatening dysrhythmias irrespective of the level; it is suggested if [Li] is over 5.0 mEq/L, significant confusion is present, or the expected time to reduce [Li] to under 1.0 mEq/L exceeds 36 hours. Continue until clinical improvement or [Li] under 1.0 mEq/L, for a minimum of 6 hours if the level is not readily measurable.^[20] Activated charcoal has no role in lithium poisoning (it is explicitly listed among poisons where charcoal is not indicated).^[48]

Long-term lithium adverse effects

• Teratogenicity — the original registry-based estimate put the relative risk of Ebstein anomaly at 400, but controlled epidemiological data show the teratogenic risk of first-trimester lithium exposure is lower than previously suggested (Cohen 1994, JAMA):^[10] in a cohort of 1,325,563 pregnancies, cardiac malformations occurred in 2.41% of lithium-exposed versus 1.15% of unexposed infants (adjusted RR 1.65, 95% CI 1.02 to 2.68), right ventricular outflow tract obstruction defects in 0.60% versus 0.18% (aRR 2.66) — and the risk was dose-dependent (RR 1.11 at 600 mg/day or less; 1.60 at 601 to 900 mg; 3.22 above 900 mg) (Patorno 2017, NEJM).^[9]

Valproate adverse effects and teratogenicity

• Teratogenicity — versus other antiepileptic drugs, valproic acid raises the risk of combined major congenital malformations (RR 2.36), neural tube defects (RR 6.54), congenital heart defects (RR 2.53), cleft lip and/or palate (RR 4.31), genitourinary anomalies (RR 3.32) and musculoskeletal anomalies (RR 2.88);^[24] gestational exposure is also associated with cognitive, language and psychomotor delay and possibly increased autism risk, making valproate perhaps the most teratogenic drug in the neuropsychiatric pharmacopeia.^[25] The 2018 MHRA statement makes valproate contraindicated in women of childbearing potential unless the conditions of a Pregnancy Prevention Programme are met and other treatments are ineffective or not tolerated.^[26]

Other mood-stabiliser adverse effects

• Carbamazepine — Stevens–Johnson syndrome / toxic epidermal necrolysis associated with the HLA-B*15:02 allele in specific Asian populations (Han Chinese, Malaysian, Thai, Vietnamese); HLA-B*15:02 genotyping is recommended by several international prescribing guidelines before carbamazepine in these groups.^[39]
• Lamotrigine — rash is the key risk: in controlled mood-disorder trials benign rash occurred in 8.3% on lamotrigine versus 6.4% on placebo, and serious rash in up to 0.13% of bipolar trial patients; prescribing guidance is to discontinue at the first sign of rash and titrate slowly.^[43][44]

Disease-related complications

• Suicide — the annual suicide rate in bipolar disorder is about 0.9%, versus 0.014% in the general population, and about 15 to 20% of patients die by suicide;^[13] across two major cohort studies bipolar disorder has been reported as the psychiatric disorder with the highest rates of completed suicide, and one in four persons with bipolar I disorder report a lifetime suicide attempt.^[51] In one large hospital cohort the suicide standardised mortality ratio for bipolar disorder was 10.26 (95% CI 7.97 to 13.00), second only to psychotic disorders.^[38] Lithium reduces suicide versus placebo (OR 0.13) and death from any cause (OR 0.38).^[6]
• Social and occupational harm during mania — debts, broken relationships, divorce, job loss, sexually transmitted infections, unwanted pregnancy, criminal/forensic consequences; in the year after hospitalisation for a manic episode two-thirds of patients do not return to work.^[51]
• Cognitive impairment — prominent cognitive deficits are documented in bipolar disorder (including among unaffected first-degree relatives) and are robustly relevant to functional outcomes.^[51]
• Comorbidity and mortality — metabolic syndrome (37%), obesity (21%), cigarette smoking (45%) and type 2 diabetes (14%) are all more prevalent; life expectancy is reduced by approximately 12 to 14 years (pooled years of potential life lost about 12.9), driven by cardiovascular disease occurring a mean of 17 years earlier and by suicide.^[13][41]

Pitfalls

• Diagnosing unipolar depression and treating with antidepressants without mood-stabiliser cover — precipitates mania, mixed states, rapid cycling. Always screen every depressed patient for past hypomania.
• Missing an organic cause of first-onset mania (thyrotoxicosis, steroids, stimulants, brain lesion). First mania over 50 is organic until proven otherwise.
• Not monitoring lithium levels and renal/thyroid function — toxicity, nephrogenic DI, hypothyroidism.
• Prescribing valproate to a woman of childbearing potential without a Pregnancy Prevention Programme.
• Stopping prophylaxis after remission — relapse is near-universal; lithium must be tapered slowly (rapid discontinuation markedly raises relapse and suicide risk).
• Confusing hypomania with normal happiness or with ADHD/borderline personality. ^[1]

Prognosis & Disposition

Bipolar disorder is a lifelong, episodic illness; rates of relapse remain high despite available treatments, and over half of patients are not adherent to treatment.^[13][51] However, early diagnosis and treatment are associated with a more favourable prognosis, and maintenance treatment changes that trajectory: in BALANCE, lithium monotherapy and combination therapy were both more likely than valproate monotherapy to prevent a new mood episode over up to 24 months (59% and 54% versus 69% had an event),^[7] and lithium reduces suicide (OR 0.13) and all-cause death (OR 0.38) versus placebo.^[6] Diagnosis and optimal treatment are often delayed by a mean of approximately 9 years after an initial depressive episode — an independent reason to screen vigorously.^[13]

Good-prognostic factors: later onset, acute (rather than insidious) onset, clear precipitant, prominent mood (rather than psychotic) symptoms, few lifetime episodes, good inter-episode function, good adherence, good social support / low expressed emotion, no substance misuse, good response to lithium, no rapid cycling.^[3]

Poor-prognostic factors: early onset, rapid cycling, mixed features, prominent psychosis, substance misuse, comorbid anxiety/personality disorder, non-adherence, poor lithium response, long delay to diagnosis/treatment (mean about 9 years), high expressed emotion, low socioeconomic status. Cognitive impairment and reduced life expectancy (approximately 12 to 14 years, from cardiovascular disease and suicide) are long-term consequences.^[13][41] Disposition: most long-term care is delivered in the community by a community mental health team (or early-intervention service for first episodes), with crisis and home treatment alternatives to admission. Admission is for risk (suicide, severe self-neglect, risk to others), severe/treatment-resistant illness, diagnostic uncertainty, or assessment — often under the Mental Health Act if capacity is impaired. Discharge planning includes relapse-prevention (early-warning-sign) plans, advance statements, crisis plans, financial/debt advice, family/carer support, and follow-up, with particular attention to the high-risk post-discharge period for suicide. ^[1]

Special Populations

• Pregnancy — the aim is mood stability for the mother weighed against fetal drug risk. Lithium: first-trimester exposure is associated with a small, dose-dependent increase in cardiac malformations including Ebstein anomaly (aRR 1.65 overall; 1.11 at 600 mg/day or less; 3.22 above 900 mg) — smaller than previously postulated, so use the lowest effective dose;^[9][10] CANMAT/ISBD 2018 gives specific advice for women at various stages of the reproductive cycle.^[14] Valproate is contraindicated (neural tube defects RR 6.54 versus other antiepileptics, plus neurodevelopmental harm) unless other options are unsuitable and a Pregnancy Prevention Programme is in place.^[24][26] Lamotrigine was the comparator reference group in the lithium cohort (cardiac malformation rate 1.39%, close to unexposed) and is among the better-characterised options in pregnancy.^[9]
• Breastfeeding — lithium excretion into breastmilk and infant serum concentrations are highly variable; most sources do not consider it an absolute contraindication in healthy full-term infants (especially over 2 months of age and with lithium monotherapy), but milk lithium can acutely harm the infant when elimination is impaired (dehydration, prematurity) — individualise with infant monitoring.^[28]
• Postpartum — postpartum psychosis/mania is a psychiatric emergency with risk of suicide and infanticide; incidence of first-onset postpartum psychosis is 0.25 to 0.6 per 1000 births, and most such women prove to lie within the bipolar spectrum — plan prophylaxis and perinatal psychiatric input.^[27]
• Elderly — CANMAT/ISBD 2018 provides specific recommendations for older adults; lithium requires renal-function-aware dosing (the standardised 12-hour level is even more critical when glomerular filtration falls), and poisoning in older patients is typically chronic or acute-on-chronic from reduced renal elimination.^[21][23]
• Adolescents — diagnosis requires a clear episodic, distinct-from-baseline change with strong family history (bipolar disorder is highly heritable; twin-study heritability about 60%); CANMAT/ISBD 2018 covers children and adolescents specifically.^[14][40]
• Substance misuse — substance use worsens course and adherence and can mimic or precipitate mania; CANMAT/ISBD 2018 addresses substance-use comorbidity specifically.^[14]

Evidence, Guidelines & Regional Differences

Landmark trials and reviews: ^[1]

• BALANCE (2010, Lancet) — randomised open-label comparison of lithium monotherapy (level 0.4 to 1.0 mmol/L), valproate monotherapy (750 to 1250 mg) and the combination for maintenance of bipolar I. A primary outcome event occurred in 54% (combination), 59% (lithium) and 69% (valproate): combination beat valproate (HR 0.59), lithium beat valproate (HR 0.71, p=0.0472), but combination was not clearly superior to lithium alone (HR 0.82, p=0.27) — supporting lithium as the first-line maintenance anchor.^[7]
• Cipriani 2011 antimanic multiple-treatments meta-analysis (Lancet) — 68 RCTs, 16,073 participants: haloperidol, risperidone, olanzapine, lithium, quetiapine, aripiprazole, carbamazepine, asenapine, valproate and ziprasidone beat placebo, gabapentin, lamotrigine and topiramate did not; haloperidol was most effective, risperidone, olanzapine and haloperidol are among the best available options, and antipsychotics overall were significantly more effective than mood stabilisers.^[5]
• Cipriani 2013 BMJ meta-analysis — 48 RCTs: lithium versus placebo reduced suicide (OR 0.13, 95% CI 0.03 to 0.66) and death from any cause (OR 0.38), with no clear benefit for deliberate self-harm; the anti-suicidal effect may operate through relapse reduction and reduced aggression/impulsivity.^[6]
• STEP-BD randomised antidepressant trial (Sachs 2007, NEJM) — adjunctive antidepressant (paroxetine or bupropion) added to a mood stabiliser gave durable recovery in 23.5% versus 27.3% with placebo (P=0.40) and similar treatment-emergent affective switch rates — no benefit from adding a standard antidepressant.^[29]
• Patorno 2017 (NEJM) — 1,325,563 Medicaid pregnancies: cardiac malformations 2.41% (lithium) versus 1.15% (unexposed), aRR 1.65, right ventricular outflow tract obstruction 0.60% versus 0.18% — smaller than previously postulated and dose-dependent.^[9]
• Cohen 1994 (JAMA) — re-evaluation of the 1970s registry claim (Ebstein relative risk 400): controlled case-control and cohort studies found no lithium exposure among four case-control series, and risk ratios of 3.0 and 1.5 for all congenital anomalies — teratogenic risk lower than previously suggested.^[10]
• CANMAT/ISBD 2018 guidelines (Yatham et al.) — first-line acute mania: lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, cariprazine (alone or in combination); first-line bipolar I depression: quetiapine, lurasidone (± lithium/divalproex), lithium, lamotrigine, or adjunctive lamotrigine; first-line maintenance: lithium, quetiapine, divalproex, lamotrigine, asenapine, aripiprazole.^[14]
• CANMAT/ISBD 2021 mixed-presentation guidelines (Yatham et al.) — dedicated recommendations for patients with mixed presentations, where antidepressant evidence is weak and mood destabilisation is a concern.^[11]

Guidelines: ^[1]

• NICE CG185 (2014, updated 2023) — UK: antipsychotic for acute mania (stop antidepressants); lithium first-line for long-term treatment; renal/thyroid monitoring every 6 months; valproate Pregnancy Prevention Programme mandatory; IPSRT/CBT/psychoeducation; ECT for refractory/severe.
• CANMAT/ISBD 2021 (Canada/International) — phase-specific hierarchies (above).
• British Association for Psychopharmacology (BAP) 2016 (Goodwin et al.) — consensus on bipolar treatment.
• WFSBP (World Federation of Societies of Biological Psychiatry) biological guidelines.
• DSM-5-TR vs ICD-11 — both retain Bipolar I, Bipolar II and cyclothymia; both dropped the old "mixed episode" diagnosis in favour of a "with mixed features" specifier; ICD-11 uses "bipolar I disorder, current episode manic" specifier codes. ^[1]

Regional differences: ^[1]

• UK (NICE) — emphasis on lithium first-line, valproate Pregnancy Prevention Programme (MHRA/EMA regulatory ban on valproate in women of childbearing potential without the programme), Early Intervention in Psychosis models, Mother and Baby Units for perinatal illness, Mental Health Act for compulsory treatment.
• North America (CANMAT/ISBD) — broader first-line lists that include lurasidone and cariprazine for bipolar depression alongside quetiapine and lithium; maintenance first-line options include lithium, quetiapine, divalproex, lamotrigine, asenapine and aripiprazole.^[14]

Exam Pearls

^{[20] [21] [23] [48] [50] [9] [24] [26]}

Exam application bank (NEET-PG / INICET)

One-line answer

Bipolar affective disorder is a chronic, relapsing episodic mood disorder defined by one or more manic or hypomanic episodes, usually alternating with major depressive episodes. Onset is usually 15 to 25 years and about three-quarters of symptomatic time is depressive; twin-study heritability is about 60%. A manic episode is elevated (or irritable) mood with increased goal-directed activity for at least 1 week (or any duration if hospitalisation is required); hypomania is at least 4 consecutive days, without marked impairment or psychosis. Acute mania is treated by stopping any antidepressant and using an antipsychotic (the more effective class) plus or minus a mood stabiliser; lithium has the strongest long-term relapse-prevention evidence, guided by the standardised 12-hour serum level, and reduces suicide versus placebo (OR 0.13). Valproate is teratogenic (neural tube defects) and contraindicated in women of childbearing potential without a Pregnancy Prevention Programme; lithium carries a small, dose-dependent Ebstein-anomaly risk (aRR 1.65). About 15 to 20% of patients die by suicide and life expectancy is reduced by roughly 12 to 14 years. ^{[6][7][9][12][13][24][26]}

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Bipolar Affective Disorder.

References51ShowHide

1. [1]Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder Lancet, 2016.PMID 26388529
2. [2]Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions Lancet, 2013.PMID 23663952
3. [3]Geddes JR, Miklowitz DJ. Treatment of bipolar disorder Lancet, 2013.PMID 23663953
4. [4]Craddock N, Sklar P. Genetics of bipolar disorder Lancet, 2013.PMID 23663951
5. [5]Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis Lancet, 2011.PMID 21851976
6. [6]Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
7. [7]Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
8. [8]Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity Br J Psychiatry, 1978.PMID 728692
9. [9]Patorno E, Huybrechts KF, Bateman BT, et al. Lithium Use in Pregnancy and the Risk of Cardiac Malformations N Engl J Med, 2017.PMID 28591541
10. [10]Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium JAMA, 1994.PMID 8031346
11. [11]Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations Bipolar Disord, 2021.PMID 34599629
12. [12]Sekhon S, Gupta V. Mood Disorder StatPearls, 2026.PMID 32644337
13. [13]Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and Treatment of Bipolar Disorder: A Review JAMA, 2023.PMID 37815563
14. [14]Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder Bipolar Disord, 2018.PMID 29536616
15. [15]Alexander J, Tharyan P, Adams C, et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine Br J Psychiatry, 2004.PMID 15231557
16. [16]Patel MX, Sethi FN, Barnes TRE, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation J Psychopharmacol, 2018.PMID 29882463
17. [17]Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients Am J Emerg Med, 2003.PMID 12811711
18. [18]Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania J Clin Psychiatry, 1993.PMID 8253698
19. [19]Houston JP, Tohen M, Degenhardt EK, et al. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study J Clin Psychiatry, 2009.PMID 19778495
20. [20]Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup Clin J Am Soc Nephrol, 2015.PMID 25583292
21. [21]Spatola L, Maringhini S, Canale C, et al. Lithium poisoning and renal replacement therapy: pathophysiology and current clinical recommendations Int Urol Nephrol, 2023.PMID 36940005
22. [22]Hsu CW, Tsai SY, Tseng PT, et al. Differences in the prophylactic effect of serum lithium levels on depression and mania in bipolar disorder: A dose-response meta-analysis Eur Neuropsychopharmacol, 2022.PMID 35158229
23. [23]Amdisen A. Serum level monitoring and clinical pharmacokinetics of lithium Clin Pharmacokinet, 1977.PMID 324690
24. [24]Yang X, Sun Y, Hua Z, et al. Safety of Valproic Acid Use in Pregnant Women: A Systematic Review and Meta-Analysis J Obstet Gynaecol Res, 2025.PMID 41161707
25. [25]Andrade C. Valproate in Pregnancy: Recent Research and Regulatory Responses J Clin Psychiatry, 2018.PMID 29873961
26. [26]Davies P, Reuber M, Grunewald R, et al. The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre Seizure, 2020.PMID 32380376
27. [27]Bergink V, Rasgon N, Wisner KL. Postpartum Psychosis: Madness, Mania, and Melancholia in Motherhood Am J Psychiatry, 2016.PMID 27609245
28. [28]Drugs and Lactation Database (LactMed) Lithium NCBI Bookshelf, 2006.PMID 30000212
29. [29]Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression N Engl J Med, 2007.PMID 17392295
30. [30]Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis J Affect Disord, 2020.PMID 32339131
31. [31]Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am J Psychiatry, 2014.PMID 24170180
32. [32]Earley W, Burgess MV, Rekeda L, et al. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study Am J Psychiatry, 2019.PMID 30845817
33. [33]Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J Clin Psychopharmacol, 2006.PMID 17110817
34. [34]Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire Am J Psychiatry, 2000.PMID 11058490
35. [35]Leão IA, Del Porto JA Cross validation with the mood disorder questionnaire (MDQ) of an instrument for the detection of hypomania in Brazil: The 32 item hypomania symptom check-list, first Revision (HCI-32-R1) J Affect Disord, 2012.PMID 22284020
36. [36]Phiel CJ, Klein PS. Molecular targets of lithium action Annu Rev Pharmacol Toxicol, 2001.PMID 11264477
37. [37]Torales J, González I, Barrios I, et al. Manic Episodes Due to Medical Illnesses: A Literature Review J Nerv Ment Dis, 2018.PMID 30124574
38. [38]Song Y, Rhee SJ, Lee H, et al. Comparison of Suicide Risk by Mental Illness: a Retrospective Review of 14-Year Electronic Medical Records J Korean Med Sci, 2020.PMID 33289369
39. [39]Gu Y, Shih STF, Geevasinga N, et al. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy JAMA Dermatol, 2024.PMID 38717780
40. [40]Johansson V, Kuja-Halkola R, Cannon TD, et al. A population-based heritability estimate of bipolar disorder - In a Swedish twin sample Psychiatry Res, 2019.PMID 31207455
41. [41]Chan JKN, Tong CHY, Wong CSM, et al. Life expectancy and years of potential life lost in bipolar disorder: systematic review and meta-analysis Br J Psychiatry, 2022.PMID 35184778
42. [42]Novick DM, Swartz HA Evidence-Based Psychotherapies for Bipolar Disorder Focus, 2019.PMID 32047369
43. [43]Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management J Clin Psychiatry, 2002.PMID 12444815
44. [44]Ketter TA, Greist JH, Graham JA, et al. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial J Clin Psychiatry, 2006.PMID 16649826
45. [45]Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Rapid cycling bipolar disorder and its treatment with valproate Can J Psychiatry, 1993.PMID 8500080
46. [46]Jalfre V, Baylé FJ, Olié JP. Rapid cycle bipolar disorder: the present situation Encephale, 1999.PMID 10434154
47. [47]Mutz J Brain stimulation treatment for bipolar disorder Bipolar Disord, 2023.PMID 36515461
48. [48]Hoegberg LCG, Gosselin S, Buckley NA, et al. Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose Clin Toxicol (Phila), 2026.PMID 41906697
49. [49]Schneck CD. Treatment of rapid-cycling bipolar disorder J Clin Psychiatry, 2006.PMID 17029493
50. [50]Lavonas EJ, Buchanan J Hemodialysis for lithium poisoning Cochrane Database Syst Rev, 2015.PMID 26374731
51. [51]Lima IMM, Peckham AD, Johnson SL Cognitive deficits in bipolar disorders: Implications for emotion Clin Psychol Rev, 2018.PMID 29195773